Skip to content
Outcomes Insights Logo
  • Our Services
    • Analyses of Observational Data
    • Commercial Strategy and Market Research
    • SEER-Medicare Analyses
  • Our Team
  • SEER-Medicare

Analyses of Observational Data

Home/Our Services/Analyses of Observational Data
Analyses of Observational DataMarc Halperin2020-10-25T16:10:08+00:00

Analyses of Observational Data

For every disease state, understanding what happens to patients over time is critical to communicating the value of a product for treating a disease (or its complications). For example, event rates are used in building models, treatment effects can be estimated in populations that were not included in clinical trials, and long-term costs of care can be estimated and compared against models for validation purposes. In particular, these kinds of analyses are critical for conducting comparative effectiveness research.

obdata

We have worked in many disease areas to analyze exposures and outcomes, and we have particular experience in oncology, cardiovascular disease, and nephrology.  We work with federally funded data like the SEER-Medicare data, the United States Renal Data System (USRDS), and the Nationwide Inpatient Sample (NIS) and other HCUP datasets. We also work with proprietary datasets from health plans and providers, and we can license specific data sets for our projects, as appropriate.

Selected publications are listed below:

  • Block GA, Chertow GM, Cooper K, Xing S, Fouqueray B, Halperin M, Danese MD, Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodial Int. 2020 Oct 5. doi: 10.1111/hdi.12887. PMID: 33016505
  • Danese MD, Pemberton-Ross P, Catterick D, Villa G.  Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom.  Eur J Prev Cardiol. 2020 Jan 21:2047487319899212. doi: 10.1177/2047487319899212
  • Khunti, K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, Seshasai SRK, Brownrigg J, Ray KK.  Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.  JAMA Netw Open. 2018;1(8):e185554. doi:10.1001/jamanetworkopen.2018.5554
  • Danese MD, Sidelnikov E, Kutikova L.  The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study.  Current Medical Research and Opinion.  2018 April doi:  10.1080/03007995.2018.1463211 [Epub ahead of print].  PMID: 29627994
  • Bradbury, B. D., Danese, M. D., Gleeson, M., & Critchlow, C. W. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin.J.Am.Soc.Nephrol. 2009. 4: 630-637.
  • Danese, M. D., Belozeroff, V., Smirnakis, K., & Rothman, K. J. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin.J.Am.Soc.Nephrol. 2008. 3: 1423-1429.

30200 Agoura Road, Suite 230
Agoura Hills, CA 91302

Phone: +1.805.498.0034

Email: mark@outins.com

Web: Outcomes Insights, Inc.

Copyright 2020 Outcomes Insights, Inc | All Rights Reserved